2025

2025/01/21

TaiMed Announces Phase 2a Clinical Study Results of Long-Acting TMB-365/TMB-380 Combination Therapy for HIV Have Been Accepted to Present at CROI 2025 Annual Conference

2025/01/08

TaiMed Biologics Announces its Long-Acting TMB-365/380 Monoclonal Antibody Combination HIV Therapy Meets All Primary Endpoints in Phase 2a Clinical Study

TaiMed HQ

TEL：02-26580058
TIME：8:00AM-18:00PM
E-mail：jchen@taimedbio.com
Add：3F.,NO.607,Ruiguang Rd.,Neihu Dist.,Taipei City 11492,Taiwan(R.O.C.)

Hsinchu Branch Office

TEL：03-6212355
TIME：8:00AM-18:00PM
ADD：No. 18, Ln. 15, Shengyi 5th Rd., Zhubei City, Hsinchu County, Taiwan (R.O.C.)
Contact CDMO Service

Download Essays Contact Privacy

TaiMed / Taimedbiologics / Clinical Development of Anti-HIV Medications / Trogarzo® / TaiMed biologics cdmo / cdmo services / HIV / cGMP Facility

256 bit SSL Encryption

Recommend using Chrome, Firefox, Safari latest version of the browser.

Designed by MIRACLEWeb Design

Contact CDMO Service